Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.70
-0.2000-2.53%
Post-market: 7.800.1000+1.30%19:30 EDT
Volume:4.07M
Turnover:31.33M
Market Cap:697.34M
PE:-3.19
High:8.02
Open:7.95
Low:7.52
Close:7.90
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:2.44
T/O Rate:5.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:13.95
PE(LYR):-2.55

Loading ...

Verastem is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Verastem Oncology Grants 399,750 Rsus, Sets New-hire Stock Option Exercise Price at $4.1

Reuters
·
Jul 03

Verastem Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03

Verastem is Maintained at Buy by BTIG

Dow Jones
·
Jul 03

Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock

TIPRANKS
·
Jun 27

Top Verastem Executives Quietly Cash Out in Fresh Stock Moves

TIPRANKS
·
Jun 25

Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says

MT Newswires Live
·
Jun 24

Verastem (VSTM) Gets a Buy from Alliance Global Partners

TIPRANKS
·
Jun 24

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

TIPRANKS
·
Jun 24

Verastem Price Target Maintained with a $18.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jun 24

BRIEF-Versus-7375 Demonstrates Clinical Activity With A Favorable Safety And Tolerability Profile In Target-D 101

Reuters
·
Jun 24

Verastem Advances VS-7375 with Promising Early Trial Data

TIPRANKS
·
Jun 24

Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors

MT Newswires Live
·
Jun 24

Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375

Dow Jones
·
Jun 24

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

TIPRANKS
·
Jun 24

Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors

Reuters
·
Jun 24

Verastem - VS-7375 Shows Anti-Tumor Activity With Anti-Egfr Therapy or Standard Chemotherapy

THOMSON REUTERS
·
Jun 24

Verastem - Co and Erasca Announce Intent to Evaluate VS-7375 With Eras-15 in Kras G12d Tumors

THOMSON REUTERS
·
Jun 24